-+ 0.00%
-+ 0.00%
-+ 0.00%

GT Biopharma Considers Phase 1b Trial of GTB-5550 With KRAS Inhibitor in Pancreatic Cancer

PUBT·11/09/2026 12:10:12
Listen to the news
GT Biopharma Considers Phase 1b Trial of GTB-5550 With KRAS Inhibitor in Pancreatic Cancer
  • GT Biopharma presented preclinical results for GTB-5550 combined with a KRAS inhibitor at SITC on November 6, 2026.
  • The combination improved pancreatic tumor control in animal models, clearing tumors in several animals while reducing local invasion and preventing metastasis.
  • A Phase 1a/1b trial of GTB-5550 monotherapy is enrolling patients across multiple tumor types, including pancreatic ductal adenocarcinoma.
  • The company is considering a future Phase 1b study combining GTB-5550 with a KRAS inhibitor in pancreatic cancer patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GT Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090700PRIMZONEFULLFEED9872520) on November 09, 2026, and is solely responsible for the information contained therein.